The findings suggest that NTP treatment can enhance T-cell responses targeting the CRC-specific antigen GC-C, potentially enhancing the immune system’s ability to recognize and eliminate cancer cells. The gene discussed is GUCY2C; the disease is colorectal carcinoma.